ULTI Ultimovacs

Ultimovacs ASA: Mandatory notification of trades by primary insider

Ultimovacs ASA: Mandatory notification of trades by primary insider

Oslo, 8 March 2024: CGS Holding AS, a closely related party of Leiv Askvig, a board member and primary insider in Ultimovacs ASA, has today sold 140,000 shares in the company at an average price of NOK 7.2507 per share. Following these transactions, CGS Holding AS holds 0 shares in Ultimovacs ASA.

Helene Sundt AS, a closely related party of Leiv Askvig, a board member and primary insider in Ultimovacs ASA, has today sold 140,000 shares in the company at an average price of NOK 7.2507 per share. Following these transactions, Helene Sundt AS holds 0 shares in Ultimovacs ASA.

Sundt AS, a closely related party of Leiv Askvig, a board member and primary insider in Ultimovacs ASA, has today sold 140,000 shares in the company at an average price of NOK 7.2507 per share. Following these transactions, Sundt AS holds 0 shares in Ultimovacs ASA.

This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities Trading Act.

Attachment



EN
08/03/2024

Underlying

ULTIUltimovacs

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ultimovacs

Geir Hiller Holom
  • Geir Hiller Holom
Free Trial
ULTI ULTIMOVACS

Ultimovacs (Sell, TP: NOK4.00) - Slower recruitment, FOCUS in focus

Total operating expenses were NOK28.6m, and cash and cash equivalents were NOK220m at end-Q1 (NOK266.6m at end-Q4 2023). The company recently announced initiatives to extend the financial runway to Q4 2025. While data from the fully recruited FOCUS trial is expected in Q3, the number of new recruited patients in the DOVACC and LUNGVAC trials was lower in Q1 versus Q4 2023. We reiterate our SELL and NOK4 target price.

05/07/24 May 7, 2024 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Alexander Krämer
05/07/24 May 7, 2024 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provid...

Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update Ultimovacs remains committed to continuing the clinical development strategy and exploring multiple pathways for UV1.The negative INITIUM results have had important consequences for the Company. Implemented cash preservation initiatives extends the anticipated financial runway to the fourth quarter of 2025, beyond the anticipated topline readout of the FOCUS and DOVACC trials. The UV1 vaccine was granted Fast Track designation from the U.S. Food and Drug Administration (FDA) and Orphan Drug desi...

May 7, 2024 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs ASA: Invitation to first quarter 2024 results webcast prese...

Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation Oslo, April 30, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its first quarter 2024 results on Tuesday, May 7, 2024. The presentation can be followed as a live webcast accessed through a link on at 14:00 CET on Tuesday, May 7, 2024, and is scheduled to conclude at 14:55 CET. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions duri...

April 30, 2024 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs Announces Poster Presentation at the 2024 American Society ...

Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting   NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. INITIUM is an Ultimovacs-sponsored randomized, comparative, multi...

April 24, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch